IMMUNITYBIO, INC. Increase (Decrease) in Notes Receivable, Related Parties
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Notes Receivable, Related Parties of -$115.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesReceivableRelatedParties · last filed 2016-03-30
- IMMUNITYBIO, INC. increase (decrease) in notes receivable, related parties for the quarter ending 2014-12-31 was $0.00.
- IMMUNITYBIO, INC. increase (decrease) in notes receivable, related parties for the quarter ending 2014-09-30 was $0.00.
- IMMUNITYBIO, INC. increase (decrease) in notes receivable, related parties for fiscal 2014 was -$115.00K.
| Period end | Increase (Decrease) in Notes Receivable, Related Parties 3 month | Increase (Decrease) in Notes Receivable, Related Parties 6 month | Increase (Decrease) in Notes Receivable, Related Parties 9 month | Increase (Decrease) in Notes Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | -$115.00K 10-K · filed 2016-03-30 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$115.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$115.00K 10-Q · filed 2015-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |